Bioxcel therapeutics appoints michael p. miller to board of directors

New haven, conn., july 05, 2022 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of michael p. miller to its board of directors, effective july 1, 2022. mr. miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as executive vice president, u.s. commercial at jazz pharmaceuticals.
BTAI Ratings Summary
BTAI Quant Ranking